This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Conlon, D. Search for Related Content Social Bookmarking                         What's this?

DREAM — a diabetes prevention study

MediNews (Diabetes) Limited, Edgbaston House, 3 Duchess Place, Edgbaston, Birmingham, B16 8NH, UK, production{at}bjdvd.com

he Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study reported in September 2006. This international, multicentre, randomised, double blind, placebo controlled, 2-by-2 factorial prospective three-year study examined the effect of rosiglitazone (8 mg/day) and/or ramipril (15 mg/day) to prevent progression to type 2 diabetes in 5,269 adults with impaired glucose tolerance (IGT), impaired fasting glucose (IFG) or both. The primary end point (incidence of diabetes or death) was reduced by 60% on rosiglitazone (11.6% on rosiglitazone vs. 26.0% on placebo, p<0.0001), and more subjects regained normoglycaemia on rosiglitazone (50.5%) than placebo (30.3%, p<0.0001). Ramipril did not alter the incidence of diabetes or death (18.1% on ramipril vs. 19.5% on placebo) but more subjects regained normoglycaemia on ramipril (42.5%) than placebo (38.2%, p=0.001). There were no apparent interactions between ramipril and rosiglitazone. Although overall cardiovascular event rates were not significantly different between rosiglitazone and placebo there was an increase in heart failure (0.5% on rosiglitazone vs. 0.1% on placebo, p<0.01) and more oedema on rosiglitazone (6.8%) than placebo (4.9%, p<0.003).

Key Words: diabetes prevention • DREAM • rosiglitazone • ramipril.

References

• Unwin N., Shaw J., Zimmet P., Alberti Kgmm. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabetic Med 2002;19:708-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• DeFronzo RA Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997;5:177-269.
• Ferrannini E., Gastaldelli A., Miyazaki Y. et al. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493-500.[Abstract/Free Full Text]
• Tuomilehto J., Lindstrom J., Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.[Abstract/Free Full Text]
• Continued on page 234 Continued from page 232
• Knowler WC, Barrett-Connor E., Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
• Zimmet P., Shaw J., Alberti Kgmm. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic Med 2003;20:693-702.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The DECODE Study Group. Glucose tolerance and all-cause mortality. Cardiology Review 2001;18:28-32.
• Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-6.[Abstract/Free Full Text]
• Yusuf S., Gerstein H., Hoogwerf B. Ramipril and the development of diabetes. JAMA 2001;285:1882-5.
• The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.[CrossRef][Medline] [Order article via Infotrieve]
• The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62.[Abstract/Free Full Text]
• DREAM slides. www.phri.ca/dream (Accessed September 2006).
• The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004;47:1519-27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517-22.[Abstract/Free Full Text]
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.[Free Full Text]
• Scheen AJ Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004;64:2537-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 5, 230-233 (2006)
DOI: 10.1177/14746514060060050501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Conlon, D. Search for Related Content Social Bookmarking                         What's this?